News | September 15, 2014

ASTRO and AANS Join Forces to Launch Stereotactic Radiosurgery Patient Registry

Comprehensive data bank will inform national treatment benchmarks for SRS

September 15, 2014 — The American Association of Neurological Surgeons (AANS) and the American Society for Radiation Oncology (ASTRO) are partnering to launch and support a national registry for stereotactic radiosurgery (SRS) treatments. The SRS patient registry will define national patterns of care in radiosurgery, with an eye to improving healthcare outcomes, supporting informed decision-making and potentially lowering the cost of care for patients. The registry project will gather data from 30 diverse, high-volume sites with data specific to SRS during the next three years. The registry will log de-identified SRS treatment information of thousands of patients affected by brain metastases, benign brain tumors and arteriovenous malformations.

“AANS and ASTRO have begun a national prospective radiosurgical registry. The registry underscores the commitment by AANS and ASTRO to enhancing quality care for our patients. It also provides new opportunities for achieving major advances in the management of patients with complex problems such as brain tumors, vascular malformations and functional disorders, which is why the Neurosurgery Research & Education Foundation (NREF) is also providing support,” said Jason Sheehan, M.D., Ph.D., FAANS, Harrison Distinguished Professor and vice-chair of neurological surgery at the University of Virginia.

ASTRO Health Policy Council Chair and a radiation oncologist at the University of Colorado, Denver, Brian Kavanagh, M.D., MPH, added, “ASTRO is excited to partner with AANS for this important project. Radiosurgery is one of the most important, high-value services we can provide to a wide range of patients for an assortment of benign and malignant cancers. The registry will give us ’big data’ that we can use to refine our current technical and patient selection guidelines with the nuanced observations that can only be derived from large patient cohorts who are followed prospectively in a registry platform.”

SRS is a minimally invasive approach utilizing imaging guidance and stereotactic principles to deliver radiation to targeted cells within the body, and it has become an important part of the neurosurgical resources for the treatment of brain metastases, benign brain tumors and arteriovenous malformations.

ASTRO and AANS will lead the Scientific Advisory Committee charged with providing strategic oversight for the registry, including but not limited to identifying and approving contributing sites that will participate; developing the plan for data collection; managing the data collection issues; developing plans for data analysis and managing data analysis issues; review and analysis of statistical reports; development of policies and procedures for responding to requests for access to registry data; and for review and approval of the publication or public presentation of data, results or conclusions resulting from the project.

Analysis of the de-identified patient data will be scientifically published, and the fully de-identified data elements will subsequently be made available in the public domain. This transparency is important to the registry and will likely stimulate secondary publications beyond what is published by the Scientific Advisory Committee.

Major sponsorship for the project has been provided by BrainLab. Additional sponsors are being sought to support the long-term efforts and expansion of the registry.

For more information: www.astro.org, www.aans.org

Related Content

Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...